安旭生物公告称，预计2025年年度实现归母净利润7100.00万元到8500.00万元，同比减少55.80%到 63.08%；预计实现扣非净利润1300万元到1560万元，同比减少58.84%到65.70%。上年同期归母净利润 为19229.53万元，扣非净利润为3789.79万元。业绩下滑主因是公司加大新技术平台投入、拓展市场及布 局海外子公司致费用增加，且美国加征关税使订单减少、成本上升，还有汇率波动等因素影响。 ...

Core Viewpoint - The company, Jindike, forecasts a significant net loss for the year 2025, with expected net profit attributable to shareholders ranging from -160 million to -180 million yuan, indicating a year-on-year increase in losses of 71.12% to 92.51% [1] Financial Performance - The company anticipates a sales revenue of approximately 112 million yuan for 2025, showing a certain degree of growth compared to the previous year [1] - The expected net profit excluding non-recurring losses is projected to be between -165 million and -185 million yuan [1] Reasons for Performance Changes - The company has increased production efficiency through early production scheduling, enhanced equipment maintenance, and improved labor discipline, which has contributed to the acceleration of flu vaccine production and shipment [1] - The company is facing increased research and development costs due to the ongoing Phase III clinical trials for the quadrivalent flu virus split vaccine (for children) and the submission of production applications for the trivalent flu virus split vaccine [1] - There are risks associated with in-process and finished products due to equipment failures and material batch differences, leading the company to decide against selling certain products [1] - The quadrivalent flu virus split vaccine has a shelf life of 12 months, necessitating the disposal of unadministered vaccines at the end of each flu season, which has resulted in asset impairment provisions totaling approximately 41.99 million yuan [1]

Core Viewpoint - The company expects a revenue of approximately 112 million in 2025, with a net loss attributable to the parent company ranging from 180 million to 160 million, representing a year-on-year increase in losses of 71.12% to 92.51% [1] Financial Performance - The company's non-GAAP net loss is projected to be between 185 million and 165 million, reflecting a year-on-year increase in losses of 55.33% to 74.16% [1] - The primary reason for the increased losses is attributed to higher R&D expenditures, particularly for the quadrivalent and trivalent influenza vaccine projects [1] Asset Management - The company has made provisions for asset impairment and inventory write-offs amounting to approximately 41.9996 million [1]

万泰生物首次募集资金总额为3.82亿元，募集资金净额为3.18亿元。万泰生物2020年4月14日发布招 股书显示，募集资金中1.50亿元用于化学发光试剂制造系统自动化技术改造及国际化认证项目，1.50亿 元用于宫颈癌疫苗质量体系提升及国际化项目，1784.81万元用于营销网络中心扩建项目。 中国经济网北京1月30日讯 万泰生物(603392.SH)昨日晚间发布2025年年度业绩预亏公告。经财务部 门初步测算，预计2025年年度实现归属于母公司所有者的净利润为-41,000万元到-33,000万元，与上年 同期相比，将出现亏损。预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净利润 为-66,000万元到-53,000万元。 2024年，万泰生物实现归属于母公司所有者的净利润10,624万元；归属于母公司所有者的扣除非经 常性损益的净利润-18,644万元。 万泰生物于2020年4月29日在上交所主板上市，公开发行股票4360万股，发行价格为8.75元/股，保 荐机构为国金证券股份有限公司。 (责任编辑：田云绯) 万泰生物首次发行费用为6365.19万元，其中，国金证券获得承销及保荐费用4346.0 ...

Group 1 - The core viewpoint of the news is that Shengnuo Bio has shown significant financial growth, with a notable increase in revenue and net profit for the first nine months of 2025 [2] - As of January 29, Shengnuo Bio's stock price decreased by 0.46%, with a trading volume of 89.92 million yuan and a net financing purchase of 3.20 million yuan [1] - The company's financing balance is 464 million yuan, accounting for 7.53% of its market capitalization, which is below the 50th percentile level over the past year, indicating a low financing position [1] Group 2 - Shengnuo Bio's revenue for the period from January to September 2025 reached 520 million yuan, representing a year-on-year growth of 53.96% [2] - The net profit attributable to the parent company for the same period was 127 million yuan, showing a substantial increase of 123.03% year-on-year [2] - The company has distributed a total of 87.14 million yuan in dividends since its A-share listing, with 63.14 million yuan distributed over the past three years [3]

分红方面，欧林生物A股上市后累计派现1543.40万元。 机构持仓方面，截止2025年9月30日，欧林生物十大流通股东中，兴全合润混合A（163406）位居第五 大流通股东，持股1544.02万股，持股数量较上期不变。兴全合宜混合A（163417）位居第七大流通股 东，持股892.14万股，持股数量较上期不变。兴全商业模式混合(LOF)A（163415）位居第十大流通股 东，持股464.12万股，为新进股东。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 融资方面，欧林生物当日融资买入430.21万元。当前融资余额3.53亿元，占流通市值的3.56%，融资余 额超过近一年80%分位水平，处于高位。 融券方面，欧林生物1月29日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量3899.00股，融券余额9.55万元，超过近一年90%分位水平，处于高位。 资料显示，成都欧林生物科技股份有限公司位于四 ...

Core Viewpoint - Watson Bio's stock experienced a decline of 1.15% on January 29, with a trading volume of 908 million yuan, indicating a challenging market environment for the company [1]. Financing Summary - On January 29, Watson Bio had a financing buy-in amount of 90.98 million yuan and a financing repayment of 114 million yuan, resulting in a net financing outflow of 22.56 million yuan [1]. - As of January 29, the total financing and securities lending balance for Watson Bio was 1.633 billion yuan, with the financing balance at 1.619 billion yuan, accounting for 7.86% of the circulating market value, which is below the 10% percentile level over the past year [1]. - In terms of securities lending, Watson Bio repaid 700 shares and sold 2,600 shares on January 29, with a selling amount of 33,500 yuan, while the remaining securities lending volume was 1.0936 million shares, with a balance of 14.0959 million yuan, exceeding the 90% percentile level over the past year [1]. Business Performance Summary - As of September 30, Watson Bio had 114,000 shareholders, a decrease of 2.75% from the previous period, while the average circulating shares per person increased by 2.83% to 13,643 shares [2]. - For the period from January to September 2025, Watson Bio reported an operating income of 1.719 billion yuan, a year-on-year decrease of 19.73%, and a net profit attributable to shareholders of 163 million yuan, down 36.24% year-on-year [2]. - Since its A-share listing, Watson Bio has distributed a total of 451 million yuan in dividends, with 95.96 million yuan distributed over the past three years [2]. Institutional Holdings Summary - As of September 30, 2025, the largest circulating shareholder of Watson Bio was E Fund's ChiNext ETF, holding 34.4714 million shares, a decrease of 5.8005 million shares from the previous period [2]. - The sixth largest circulating shareholder was Southern CSI 500 ETF, holding 23.2821 million shares, down by 530,100 shares compared to the previous period [2]. - The eighth largest circulating shareholder was the China National Bio-Medical Index A, holding 23.0678 million shares, a decrease of 390,870 shares from the previous period, while Hong Kong Central Clearing Limited, the tenth largest shareholder, increased its holdings by 233,600 shares to 20.2008 million shares [2].

证券代码：688105 证券简称：诺唯赞 公告编号：2026-002 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 经南京诺唯赞生物科技股份有限公司（以下简称"公司"）财务部门初步测算，预计公司2025年度： 1. 实现归属于母公司所有者的净利润-2,000万元至-1,000万元。 2. 实现归属于母公司所有者的扣除非经常性损益的净利润-8,500万元至-7,000万元。 三、本期业绩变化的主要原因 2025年度，公司预计出现亏损，主要原因如下： 1.报告期内，预计实现的营业收入与上年同期基本持平，主要系公司生物制品类产品增值税率由3%调 整至13%，对整体营收与盈利产生不利影响。 2.报告期内，公司积极应对外部环境变化影响，加强技术与产品研发，优化降本增效举措，提升经营效 率，不断巩固公司科技创新实力与市场竞争力。同时，公司保持市场投入强度，积极拓展创新业务与海 外市场，销售费用同比有所增长，对当期经营结果有一定 ...

Group 1 - The company expects a net loss attributable to shareholders of the parent company for the year 2025, estimated at -5.23 billion yuan [3] - The net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be -5.58 billion yuan [4] - The performance forecast is based on preliminary calculations and has not been audited by a registered accountant [5] Group 2 - In the same period last year, the total profit was -5.85 billion yuan, with a net profit attributable to shareholders of the parent company at -5.29 billion yuan [6] - The earnings per share for the previous year were -2.69 yuan [7] Group 3 - The main reasons for the expected loss in 2025 include significant investments in the strategic development of various technology platforms, reduced contributions from foreign exchange losses and interest income, and increased depreciation and impairment losses [8] - Normal investment income from financial management activities had a non-operating impact during the reporting period [9]

Group 1: Strategy Overview - The report emphasizes the resilience of the A-share market amidst multiple overseas risks and signals of regulatory easing in China, suggesting that the relationship between market performance and regulatory changes warrants further consideration [5][12] - It highlights the significant outperformance of the A-share market compared to other major indices, particularly the CSI 300, which has faced substantial redemption pressure [5][12] - The report suggests that investors should not overly worry about the CSI 300's performance, as it has already aligned with regulatory easing requirements, reducing the necessity for further pressure [5][12] Group 2: Economic Insights - China's exports continued to show strong performance in December, driven by overseas investment during a global easing cycle, positively impacting sectors like electrical and mechanical equipment [6][13] - Domestic consumption is recovering, with a rebound in per capita consumer spending in the fourth quarter, aligning with the report's annual strategy predictions [6][13] - The report notes that recent government policies aimed at boosting domestic demand and stabilizing real estate are expected to support synchronized recovery in both domestic and external demand [6][13] Group 3: Asset Allocation and Investment Recommendations - The report identifies a dual focus for 2026 on physical assets and Chinese assets, with thematic investments being essential [7][16] - Recommended sectors include physical assets such as copper, aluminum, tin, gold, lithium, and oil, alongside Chinese equipment export chains like electrical grid equipment and renewable energy [7][16] - The report also highlights sectors benefiting from capital market expansion and improving long-term asset returns, such as non-bank financials and consumer sectors like aviation and duty-free retail [7][16] Group 4: Company-Specific Insights - **Yunnan Aluminum Co. (000807.SZ)**: The report recommends a long-term investment due to favorable conditions for aluminum exports and a strong balance sheet, with potential for increased dividends [18] - **Hua Aluminum (600301.SH)**: The company is seen as a strong growth candidate due to rising tin and antimony prices and its position as a key beneficiary of metal consolidation in Guangxi [19] - **Yingliu Co. (603308.SH)**: The report anticipates a surge in global gas turbine demand, positioning the company to increase its market share in turbine blades [20] - **Shangfeng Cement (000672.SZ)**: The company is recognized for its strong cash flow from cement operations and potential for significant dividends [21] - **Pop Mart (9992.HK)**: The company is expected to maintain rapid growth in the entertainment market through IP incubation and diverse monetization strategies [22] - **China Duty Free Group (601888.SH)**: The company is projected to strengthen its market position in the duty-free sector, benefiting from increased inbound tourism and overseas expansion [24] - **China Southern Airlines (1055.HK)**: The airline is expected to benefit from improved industry supply-demand dynamics and a large fleet size [25] - **Li Auto (2015.HK)**: The company is focusing on advancements in AI and smart driving technology, with expectations for increased vehicle sales [26] - **Lante Optics (688127.SH)**: The company is positioned to benefit from strong demand in automotive and smart imaging sectors [27] - **InnoCare Pharma (9606.HK)**: The company is advancing in the ADC field with a robust pipeline and partnerships, with several products nearing clinical registration [29]